ClinicalTrials.gg
CompletedNCT06675188Updated Aug 3, 2025

A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants

A Phase 1 interventional study of PF-07275315 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Pfizer · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to learn if the study medicine (called PF-07275315) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who:

  • Are between 18 to 65 years of age.
  • Are Chinese participants who are overtly healthy as determined by medical evaluation.
  • Have a BMI (body mass index) of 19 to 28 kilogram per meter squared; and a total body weight of more than50 kilograms (110 pounds).

All participants in this study will receive study medicine. About three-fourths will receive PF-07275315 and one-fourth will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The study medicine will be given as an IV infusion (directly into a vein) at the study clinic only one time.

The study will compare the experiences of people receiving PF-07275315 to those of people who do not. This will help see if PF-07275315 is safe and how it behaves inside the human body.

Participants will take part in this study for up to 181 days. During this time, the participants will stay at the study clinic for 5 days. After the stay, the participants will have 8 study visits at the study clinic.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Healthy male and female participants aged 18 to 65 years.
  2. (BMI) of 19-27.9 kilogram per meter squared, inclusive, and a total body weight >50 kilograms (110 pounds).
  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
  4. Capable of giving signed .

Key Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
  2. History of (HIV) infection, , , or syphilis; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb), or syphilis.
  3. Evidence of active, latent, untreated or inadequately treated infection with Mycobacterium tuberculosis (TB).
  4. Participants with any acute or chronic infections or infection history as per protocol required.
  5. History of fever within 7 days prior to dosing.
  6. Recent exposure to live or attenuated vaccines within 28 days of the screening visit.
  7. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  8. Use of prohibited concomitant medication within 7 days or 5 half-lives (whichever is longer) prior to the administration of PF-07275315.
  9. Previous administration with an product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the administration of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.
  10. A positive urine drug test.
  11. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) following at least 5 minutes of supine rest.
  12. Standard 12 lead (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  13. Participants with any protocol defined abnormalities in clinical laboratory tests at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    PF-07275315

    Participants will receive a single dose of PF-07275315 via IV infusion

    Drug: PF-07275315

  • Placebo comparator
    Placebo

    Participants will receive a single dose of placebo via IV infusion

    Other: Placebo

Interventions

  • PF-07275315 solution for injection (single use only)

  • OtherPlacebo

    Placebo solution for injection (single use only)

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to Day 181

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: Up to Day 181

  3. area under the concentration-time curve from time 0 to 336 hours (AUC336)

    Time frame: Up to Day 181

  4. Area under the concentration-time curve from time 0 to infinity (AUCinf)

    Time frame: Up to Day 181

  5. Area under the concentration-time curve from 0 to time of last measurable concentration (AUClast)

    Time frame: Up to Day 181

  6. Terminal phase half-life (t½)

    Time frame: Up to Day 181

  7. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to Day 181

  8. Incidence of treatment-emergent serious adverse events (SAEs)

    Time frame: Up to Day 181

  9. Incidence of abnormal and clinically relevant changes in vital signs

    Time frame: Up to Day 181

  10. Incidence of abnormal and clinically relevant changes in electrocardiogram

    Time frame: Up to Day 181

  11. Incidence of abnormal and clinically relevant changes in laboratory assessments

    Time frame: Up to Day 181

Secondary outcomes

  1. Clearance (CL) of PF-07275315

    Time frame: Up to Day 181

  2. volume of distribution (Vss)

    Time frame: Up to Day 181

  3. mean residence time (MRT)

    Time frame: Up to Day 181

  4. Incidence of the Development of Anti-Drug Antibodies (ADA) against PF-07275315

    Time frame: Up to Day 181

  5. Incidence of the neutralizing antibodies (NAb) against PF-07275315, if appropriate and feasible

    Time frame: Up to Day 181

  6. Change from baseline in serum levels of chemokine (C-C motif) ligand 17 (CCL17) / thymus and activation regulated chemokine (TARC)

    Time frame: Up to Day 181

  7. Change from baseline in serum levels of total immunoglobulin E (IgE)

    Time frame: Up to Day 181

07

Study locations

1 site
  • Huashan Hospital,Fudan University
    Shanghai, Shanghai Municipality 201107, China
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jul 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 5, 2024
StartActual
Jan 6, 2025
Primary completionActual
Jul 14, 2025
CompletionActual
Jul 14, 2025
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06675188
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Jan 6, 2025
Primary completion
Jul 14, 2025
Completion
Jul 14, 2025
Last update
Aug 3, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tilrekimig

Start the discussion